Amazon Studios Orders Fourth Season of the Award-Winning Comedy The Marvelous Mrs. Maisel
13.12.2019 02:10:00 EET | Business Wire | Press release
(NASDAQ:AMZN) – Amazon Studios announced today that it has ordered a fourth season of the Emmy and Golden Globe-Award winning comedy The Marvelous Mrs. Maisel. The third season premiered Friday, Dec. 6 on Amazon Prime Video in more than 200 countries and territories worldwide. The Marvelous Mrs. Maisel received two Golden Globe nominations this week, for Best Television Series, Musical or Comedy, and for star Rachel Brosnahan for Best Performance by an Actress in a Series, Musical or Comedy.
“We were thrilled to hear that for the fourth time, we do not have to pack up and vacate the premises,” said Creator and Executive Producer Amy Sherman-Palladino and Executive Producer Daniel Palladino. “We’d like to thank Amazon for all their faith and support, their partnership and enthusiasm, and for letting us hang with our favorite people, the cast and crew of Maisel, for a little while longer.”
“The Marvelous Mrs. Maisel has been a worldwide phenomenon, and Season 3 has been no exception, with the series’ most watched opening weekend ever. We’re so happy that our Prime Video customers will get to see Midge’s story continue in Season 4,” said Jennifer Salke, Head of Amazon Studios. “Amy and Dan have created such funny, charming, relatable characters, all with their inimitable wit and eye for detail, and our customers around the world will be delighted to have another season in the world of The Marvelous Mrs. Maisel.”
In Season Three of The Marvelous Mrs. Maisel, Midge and Susie discover that life on tour with Shy is glamorous but humbling, and they learn a lesson about show business they’ll never forget. Joel struggles to support Midge while pursuing his own dreams, Abe embraces a new mission and Rose learns she has talents of her own.
The Marvelous Mrs. Maisel is the winner of sixteen Emmy Awards including Outstanding Comedy series, three Golden Globes including Best TV Series—Comedy, five Critics’ Choice Awards including Best Comedy Series, two PGA Awards, a WGA Award, and a Peabody Award.
The Marvelous Mrs. Maisel stars Emmy and Golden Globe winner Rachel Brosnahan, Golden Globe winner and four-time Emmy winner Tony Shalhoub, two-time Emmy winner Alex Borstein, Emmy nominee Marin Hinkle, Michael Zegen, Kevin Pollak, Caroline Aaron and Emmy winner Jane Lynch.
Prime members can stream The Marvelous Mrs. Maisel at www.amazon.com/Maisel Members can also download the series to mobile devices for offline viewing at no additional cost to their membership. The series is a global release and available on PrimeVideo.com for Prime Video members in more than 200 countries and territories. Watch where and when you want with the Prime Video app on your smart TV, mobile device, Fire TV, Fire tablet, Apple TV, Chromecast, game consoles, Comcast X1 or from the web. For a complete list of compatible devices, visit amazon.com/howtostream. Customers who are not already Prime members can sign up for a free trial at www.amazon.com/prime.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005869/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom